Newsletter Subscription

Enter Name and Email

10 September 2013 Parkinson's Disease Therapeutics Conference in New York City

Adrian Newman-Tancredi, PhD, DSc, will be presenting at the 7th Annual Parkinson's Disease Therapeutic Conference in New York on Thursday 24 October 2013.

The 250-attendee meeting, organized under the auspices of the Michael J. Fox Foundation and the New York Academy of Sciences, will be chaired by C. Warren Olanow, MD, FRCPC of Mount Sinai School of Medicine, and will highlight novel advances in basic and translational research that impact the treatment and diagnosis of Parkinson's disease (PD). Adrian's presentation will focus on novel serotonergic drugs that have the potential to attenuate the troublesome dyskinesia that is observed in many PD patients upon prolonged treatment with L-DOPA.

As Chief Scientific Officer of the bioscience start-up company, Neurolixis, Adrian is Principal Investigator on a project supported by two Michael J Fox Foundation grants. If this project is successful, Neurolixis will take a novel, highly selective and efficacious serotonin 5-HT1A agonist into clinical proof-of-concept trials in PD patients.

For detailed meeting information see the New York Academy of Sciences announcement.

If you are attending the conference, Adrian would be happy to meet and discuss with you: Contact.